Injectable platelet rich fibrin in androgenetic alopecia ( Patterened baldness)

To study the efficacy and safety of injectable platelet rich fibrin in androgenetic alopecia- An interventional study - NIL

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056292

Enrollment

Registered

2023-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Injection of injectable Platelet rich firbrin: Injection of platelet rich fibrin into the scalp prepared from patients own blood Intervention2: Oral medication and topical medication: M

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to give informed consent 2. Patients of either gender aged 18 to 60 years. 3. Androgenetic Alopecia in males with Norwood-Hamilton grade 2-6 and females beyond grade 1 according to Ludwigâ??s scale. 4. Patients willing for follow up.

Exclusion criteria

Exclusion criteria: 1. patients with Alopecia other than Androgenetic Alopecia 2. Patients with active infection at the local site 3. Patients with keloidal tendency 4. Patients with blood coagulopathies and platelets count below 1,50,000cell/mm3 5. Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame
Trichoscopic improvement/ maintenance in the hair density / diameterTimepoint: 4 sessions at 2 weekly intervals Final assessment at the end of 3 months	—

Secondary

Measure	Time frame
Improvements in visual analogue scale Improvements in global photographyTimepoint: At the end of 3 months	—

Countries

India

Contacts

Public ContactDr Sahana N C

Bangalore medical college and research institute

bhatt.sahana5@gmail.com9449998099

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026